Skip to Main Content Subscribe

Featured

Cancer HealthCast 47m listen

An Intersectional Look at Anal Cancer and HIV

Share
HealthCast: An Intersectional Look at Anal Cancer and HIV
NCI’s ANCHOR study discovered that early treatment of precancerous lesions can cut anal cancer rates by more than half in people with HIV.

In June, a study supported by the National Cancer Institute found that for people with HIV, early treatment of precancerous anal lesions caused by human papillomavirus (HPV) can cut rates of anal cancer incidence by more than half. These findings from the Anal Cancer/HSIL Outcomes Research (ANCHOR) study are creating secondary prevention options for those at risk for anal cancer who have not received the HPV vaccine. We look into the history of the study and what its work means for those at risk for anal cancer.
HealthCast: An Intersectional Look at Anal Cancer and HIV
Featuring:
  • Dr. Joel Palefsky
    Dr. Joel Palefsky Professor of Medicine University of California San Francisco
  • Dr. Robert Yarchoan
    Dr. Robert Yarchoan Director, Office of HIV and AIDS Malignancy NCI
Woman listening to podcast

Stay in the Know

Subscribe now to receive our newsletters

Related Content